🇺🇸 protease inhibitors in United States
35 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 35
Most-reported reactions
- Blood Creatinine Increased — 5 reports (14.29%)
- Hepatic Enzyme Increased — 5 reports (14.29%)
- Drug Interaction — 4 reports (11.43%)
- Renal Failure Acute — 4 reports (11.43%)
- Fatigue — 3 reports (8.57%)
- Hepatic Failure — 3 reports (8.57%)
- Osteonecrosis — 3 reports (8.57%)
- Pain — 3 reports (8.57%)
- Rhabdomyolysis — 3 reports (8.57%)
- Anaemia — 2 reports (5.71%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is protease inhibitors approved in United States?
protease inhibitors does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for protease inhibitors in United States?
French National Agency for Research on AIDS and Viral Hepatitis is the originator. The local marketing authorisation holder may differ — check the official source linked above.